178 related articles for article (PubMed ID: 35182475)
1. Real-world effectiveness of antipsychotic doses for relapse prevention in patients with first-episode schizophrenia in Finland: a nationwide, register-based cohort study.
Taipale H; Tanskanen A; Correll CU; Tiihonen J
Lancet Psychiatry; 2022 Apr; 9(4):271-279. PubMed ID: 35182475
[TBL] [Abstract][Full Text] [Related]
2. Optimal Doses of Specific Antipsychotics for Relapse Prevention in a Nationwide Cohort of Patients with Schizophrenia.
Taipale H; Tanskanen A; Luykx JJ; Solmi M; Leucht S; Correll CU; Tiihonen J
Schizophr Bull; 2022 Jun; 48(4):774-784. PubMed ID: 35524479
[TBL] [Abstract][Full Text] [Related]
3. Long-term treatment with clozapine and other antipsychotic drugs and the risk of haematological malignancies in people with schizophrenia: a nationwide case-control and cohort study in Finland.
Tiihonen J; Tanskanen A; Bell JS; Dawson JL; Kataja V; Taipale H
Lancet Psychiatry; 2022 May; 9(5):353-362. PubMed ID: 35334224
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological treatments and risk of readmission to hospital for unipolar depression in Finland: a nationwide cohort study.
Tiihonen J; Tanskanen A; Hoti F; Vattulainen P; Taipale H; Mehtälä J; Lähteenvuo M
Lancet Psychiatry; 2017 Jul; 4(7):547-553. PubMed ID: 28578901
[TBL] [Abstract][Full Text] [Related]
5. Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia.
Tiihonen J; Mittendorfer-Rutz E; Majak M; Mehtälä J; Hoti F; Jedenius E; Enkusson D; Leval A; Sermon J; Tanskanen A; Taipale H
JAMA Psychiatry; 2017 Jul; 74(7):686-693. PubMed ID: 28593216
[TBL] [Abstract][Full Text] [Related]
6. Comparative Effectiveness of Antipsychotic Drugs for Rehospitalization in Schizophrenia-A Nationwide Study With 20-Year Follow-up.
Taipale H; Mehtälä J; Tanskanen A; Tiihonen J
Schizophr Bull; 2018 Oct; 44(6):1381-1387. PubMed ID: 29272458
[TBL] [Abstract][Full Text] [Related]
7. Standard versus reduced dose of antipsychotics for relapse prevention in multi-episode schizophrenia: a systematic review and meta-analysis of randomised controlled trials.
Højlund M; Kemp AF; Haddad PM; Neill JC; Correll CU
Lancet Psychiatry; 2021 Jun; 8(6):471-486. PubMed ID: 34023019
[TBL] [Abstract][Full Text] [Related]
8. 20-Year Nationwide Follow-Up Study on Discontinuation of Antipsychotic Treatment in First-Episode Schizophrenia.
Tiihonen J; Tanskanen A; Taipale H
Am J Psychiatry; 2018 Aug; 175(8):765-773. PubMed ID: 29621900
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study.
Tiihonen J; Wahlbeck K; Lönnqvist J; Klaukka T; Ioannidis JP; Volavka J; Haukka J
BMJ; 2006 Jul; 333(7561):224. PubMed ID: 16825203
[TBL] [Abstract][Full Text] [Related]
10. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia.
Tiihonen J; Haukka J; Taylor M; Haddad PM; Patel MX; Korhonen P
Am J Psychiatry; 2011 Jun; 168(6):603-9. PubMed ID: 21362741
[TBL] [Abstract][Full Text] [Related]
11. Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study.
Morrison AP; Pyle M; Maughan D; Johns L; Freeman D; Broome MR; Husain N; Fowler D; Hudson J; MacLennan G; Norrie J; Shiers D; Hollis C; James A;
Lancet Psychiatry; 2020 Sep; 7(9):788-800. PubMed ID: 32649925
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
Stargardt T; Weinbrenner S; Busse R; Juckel G; Gericke CA
J Ment Health Policy Econ; 2008 Jun; 11(2):89-97. PubMed ID: 18509216
[TBL] [Abstract][Full Text] [Related]
13. Women with Schizophrenia-Spectrum Disorders After Menopause: A Vulnerable Group for Relapse.
Sommer IE; Brand BA; Gangadin S; Tanskanen A; Tiihonen J; Taipale H
Schizophr Bull; 2023 Jan; 49(1):136-143. PubMed ID: 36198044
[TBL] [Abstract][Full Text] [Related]
14. Safety of Antipsychotic Polypharmacy Versus Monotherapy in a Nationwide Cohort of 61,889 Patients With Schizophrenia.
Taipale H; Tanskanen A; Tiihonen J
Am J Psychiatry; 2023 May; 180(5):377-385. PubMed ID: 36945825
[TBL] [Abstract][Full Text] [Related]
15. Associations between antipsychotic use, substance use and relapse risk in patients with schizophrenia: real-world evidence from two national cohorts.
Lähteenvuo M; Luykx JJ; Taipale H; Mittendorfer-Rutz E; Tanskanen A; Batalla A; Tiihonen J
Br J Psychiatry; 2022 Dec; 221(6):758-765. PubMed ID: 36004532
[TBL] [Abstract][Full Text] [Related]
16. Antipsychotic Use and Risk of Low-Energy Fractures in People With Schizophrenia: A Nationwide Nested Case-Control Study in Finland.
Solmi M; Lähteenvuo M; Correll CU; Tanskanen A; Tiihonen J; Taipale H
Schizophr Bull; 2023 Jan; 49(1):78-89. PubMed ID: 36334051
[TBL] [Abstract][Full Text] [Related]
17. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].
Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I
Encephale; 2005; 31(2):235-46. PubMed ID: 15959450
[TBL] [Abstract][Full Text] [Related]
18. Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia.
Tiihonen J; Taipale H; Mehtälä J; Vattulainen P; Correll CU; Tanskanen A
JAMA Psychiatry; 2019 May; 76(5):499-507. PubMed ID: 30785608
[TBL] [Abstract][Full Text] [Related]
19. Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland.
Taipale H; Solmi M; Lähteenvuo M; Tanskanen A; Correll CU; Tiihonen J
Lancet Psychiatry; 2021 Oct; 8(10):883-891. PubMed ID: 34474013
[TBL] [Abstract][Full Text] [Related]
20. Relapse and rehospitalisation rates in patients with schizophrenia: effects of second generation antipsychotics.
Csernansky JG; Schuchart EK
CNS Drugs; 2002; 16(7):473-84. PubMed ID: 12056922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
